Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL)

Poster Presentation at 2016 ASH Annual Meeting

The outcome of MCL patients (pts) has improved over the last three decades, although this is debated outside clinical trials (Chandran, Leuk Lymphoma Aug 2012; Smith, Br J Cancer. April 2015). The Mantle Cell International Prognostic Index (MIPI) (Hoster, Blood Jan 2008) is based on 4 variables which predict survival: age (host factor), PS (tumor/host), LDH (tumor burden) and WBC (leukemic phase). The additional value of including co-morbidities into risk stratification has not been fully explored. 

Authors: Goy A, Wu T, Hansen E, Arunajadai S, Protomastro E, Valentinetti M, Murphy M, Smith JE, Pe Benito R, Hasan A, Suryadevara K, Feldman T, Skarbnik AP, Leslie LA, Rowley SD, Donato ML, Pecora AL, Goldberg SL

Thank you signing up!
Oops! Something went wrong while submitting the form